FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280609529> ?p ?o ?g. }

• W4280609529 abstract "Introduction: In 2021, two phase III clinical trials confirmed that toripalimab or camrelizumab combined with gemcitabine and cisplatin (TGP or CGP) provide more benefits in the first-line treatment of R/M NPC than GP. Fortunately, TGP and CGP were recently approved as first-line treatments for cases experiencing R/M NPC by the China National Medical Products Administration in 2021. However, due to the high cost and variety of treatment options, the promotion of chemo-immunotherapeutics in the treatment of R/M NPC remains controversial. Therefore, we performed a cost-effectiveness assessment of the two newly approved treatment strategies to assess which treatments provide the greatest clinical benefits at a reasonable cost. Methods: A cost-effectiveness analysis and network meta-analysis network meta-analysis was conducted based on the JUPITER-02 and CAPTAIN-first Phase 3 randomized clinical trials. A Markov model was expanded for the evaluation of the effectiveness and cost of TGP, CGP, and GP chemotherapy with a 10-years horizon and measured the health achievements in quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and life-years (LYs). We constructed a treatment strategy and other parameters based on two clinical trials and performed one-way and probabilistic sensitivity experiments for the evaluation of the uncertainty in the model. Results: For the model of patients with treatment-R/M NPC, TGP was associated with a total cost of $48,525 and 2.778 QALYs (4.991 LYs), leading to an ICER of $15,103 per QALY ($10,321 per LY) compared to CGP. On comparing the GP chemotherapy, we found TGP and CGP incurred substantial health costs, resulting in ICERs of $19,726 per QALY and $20,438 per QALY, respectively. The risk of adverse events (AEs) and the price of the drugs had significant impacts on the ICER. At the assumed willingness-to-pay (WTP) threshold of $35,673 per QALY, there were approximately 75.8 and 68.5% simulations in which cost-effectiveness was achieved for TGP and CGP, respectively. Conclusion: From the Chinese payer's perspective, TGP is more possible to be a cost-effective regimen compared with CGP and GP for first-line treatment of patients with R/M NPC at a WTP threshold of $35,673 per QALY." @default.
• W4280609529 created "2022-05-22" @default.
• W4280609529 creator A5019483797 @default.
• W4280609529 creator A5022167110 @default.
• W4280609529 creator A5029040358 @default.
• W4280609529 creator A5050501022 @default.
• W4280609529 creator A5060803691 @default.
• W4280609529 creator A5073100070 @default.
• W4280609529 date "2022-05-20" @default.
• W4280609529 modified "2023-09-25" @default.
• W4280609529 title "Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis" @default.
• W4280609529 cites W1642362876 @default.
• W4280609529 cites W2005295931 @default.
• W4280609529 cites W2018873263 @default.
• W4280609529 cites W2093974625 @default.
• W4280609529 cites W2111999709 @default.
• W4280609529 cites W2126499930 @default.
• W4280609529 cites W2150434794 @default.
• W4280609529 cites W2222937713 @default.
• W4280609529 cites W2306418640 @default.
• W4280609529 cites W2512237822 @default.
• W4280609529 cites W2529484692 @default.
• W4280609529 cites W2735001208 @default.
• W4280609529 cites W2766450847 @default.
• W4280609529 cites W2885745186 @default.
• W4280609529 cites W2917837889 @default.
• W4280609529 cites W2947165726 @default.
• W4280609529 cites W2977392388 @default.
• W4280609529 cites W2979480540 @default.
• W4280609529 cites W2980598473 @default.
• W4280609529 cites W2982369800 @default.
• W4280609529 cites W2982375114 @default.
• W4280609529 cites W2982607788 @default.
• W4280609529 cites W2984096159 @default.
• W4280609529 cites W2984538501 @default.
• W4280609529 cites W2986633517 @default.
• W4280609529 cites W2987508808 @default.
• W4280609529 cites W2988735335 @default.
• W4280609529 cites W2989379683 @default.
• W4280609529 cites W2990398119 @default.
• W4280609529 cites W2998836845 @default.
• W4280609529 cites W3023184521 @default.
• W4280609529 cites W3024392979 @default.
• W4280609529 cites W3095816718 @default.
• W4280609529 cites W3111665711 @default.
• W4280609529 cites W3112700526 @default.
• W4280609529 cites W3113781210 @default.
• W4280609529 cites W3119410074 @default.
• W4280609529 cites W3121907365 @default.
• W4280609529 cites W3154757118 @default.
• W4280609529 cites W3157558500 @default.
• W4280609529 cites W3174457883 @default.
• W4280609529 cites W3177205810 @default.
• W4280609529 cites W3181752997 @default.
• W4280609529 cites W3188488521 @default.
• W4280609529 cites W3190270536 @default.
• W4280609529 cites W3200231835 @default.
• W4280609529 cites W3205552647 @default.
• W4280609529 cites W3212936283 @default.
• W4280609529 cites W4200442407 @default.
• W4280609529 cites W3094439977 @default.
• W4280609529 doi "https://doi.org/10.3389/fphar.2022.858207" @default.
• W4280609529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35668931" @default.
• W4280609529 hasPublicationYear "2022" @default.
• W4280609529 type Work @default.
• W4280609529 citedByCount "8" @default.
• W4280609529 countsByYear W42806095292022 @default.
• W4280609529 countsByYear W42806095292023 @default.
• W4280609529 crossrefType "journal-article" @default.
• W4280609529 hasAuthorship W4280609529A5019483797 @default.
• W4280609529 hasAuthorship W4280609529A5022167110 @default.
• W4280609529 hasAuthorship W4280609529A5029040358 @default.
• W4280609529 hasAuthorship W4280609529A5050501022 @default.
• W4280609529 hasAuthorship W4280609529A5060803691 @default.
• W4280609529 hasAuthorship W4280609529A5073100070 @default.
• W4280609529 hasBestOaLocation W42806095291 @default.
• W4280609529 hasConcept C112930515 @default.
• W4280609529 hasConcept C126322002 @default.
• W4280609529 hasConcept C127454912 @default.
• W4280609529 hasConcept C142724271 @default.
• W4280609529 hasConcept C143998085 @default.
• W4280609529 hasConcept C18903297 @default.
• W4280609529 hasConcept C2776125615 @default.
• W4280609529 hasConcept C2776694085 @default.
• W4280609529 hasConcept C2778997737 @default.
• W4280609529 hasConcept C2780258809 @default.
• W4280609529 hasConcept C3019080777 @default.
• W4280609529 hasConcept C509974204 @default.
• W4280609529 hasConcept C515549039 @default.
• W4280609529 hasConcept C535046627 @default.
• W4280609529 hasConcept C64332521 @default.
• W4280609529 hasConcept C71924100 @default.
• W4280609529 hasConcept C86803240 @default.
• W4280609529 hasConceptScore W4280609529C112930515 @default.
• W4280609529 hasConceptScore W4280609529C126322002 @default.
• W4280609529 hasConceptScore W4280609529C127454912 @default.
• W4280609529 hasConceptScore W4280609529C142724271 @default.
• W4280609529 hasConceptScore W4280609529C143998085 @default.
• W4280609529 hasConceptScore W4280609529C18903297 @default.
• W4280609529 hasConceptScore W4280609529C2776125615 @default.

• next